{{Rsnum
|rsid=1041983
|Gene=NAT2
|Chromosome=8
|position=18400285
|Orientation=plus
|ReferenceAllele=C
|GMAF=0.3572
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=NAT2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 51.3 | 37.2 | 11.5
| HCB | 37.2 | 48.2 | 14.6
| JPT | 49.1 | 34.8 | 16.1
| YRI | 25.2 | 47.6 | 27.2
| ASW | 28.1 | 52.6 | 19.3
| CHB | 37.2 | 48.2 | 14.6
| CHD | 40.7 | 44.4 | 14.8
| GIH | 31.7 | 51.5 | 16.8
| LWK | 36.4 | 43.6 | 20.0
| MEX | 47.4 | 45.6 | 7.0
| MKK | 32.7 | 51.9 | 15.4
| TSI | 49.0 | 40.2 | 10.8
| HapMapRevision=28
}}

[[rs1041983]] is a SNP in the [[NAT2]] gene, potentially encoding a variant detoxifying protein known as an N-acetyltransferase, but which [[NAT2]] variant depends on which other [[NAT2]] SNPs were also inherited. See the discussion of the [[NAT2]] gene for a more complete explanation.

The risk allele for this SNP is [[rs1041983]](T).

{{ neighbor
| rsid = 1801279
| distance = 91
}}
{{ neighbor
| rsid = 1801280
| distance = 59
}}

{{PharmGKB
|RSID=rs1041983
|Name_s=NAT2:282C>T, one of 2 varriants comprising NAT2*6A
|Gene_s=NAT2
|Feature=
|Evidence=PubMed ID:19356010
|Annotation=in vitro study; PK: 22-fold reduction in Vmax vs wild type
|Drugs=clonazepam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110592
}}

{{PharmGKB
|RSID=rs1041983
|Name_s=NAT2:282C>T
|Gene_s=NAT2
|Feature=
|Evidence=PubMed ID:17434923; Web Resource:http://louisville.edu/medschool/pharmacology/Human.NAT2.pdf
|Annotation=May be important for rapid vs. slow acetylator phenotype. Historically, homozygous T allele has been defined as rapid acetylator phenotype, but there is conflicting evidence.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145839
}}

{{PMID Auto
|PMID=22092036
|Title=Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
|OA=1
}}

{{PMID Auto
|PMID=16112301
|Title=NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
|OA=1
}}

{{PMID Auto
|PMID=16400611
|Title=Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.
|OA=1
}}

{{PMID Auto
|PMID=16416399
|Title=Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.
|OA=1
}}

{{PMID Auto
|PMID=16847422
|Title=Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=17335581
|Title=Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus.
|OA=1
}}

{{PMID Auto
|PMID=18547414
|Title=Genotyping panel for assessing response to cancer chemotherapy.
|OA=1
}}

{{PMID Auto
|PMID=18680467
|Title=Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.
|OA=1
}}

{{PMID Auto
|PMID=18773084
|Title=Multiple advantageous amino acid variants in the NAT2 gene in human populations.
|OA=1
}}

{{PMID Auto
|PMID=18936436
|Title=Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994.
|OA=1
}}

{{PMID Auto
|PMID=20043821
|Title=Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.
|OA=1
}}

{{PMID Auto
|PMID=21750470
|Title=Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.
}}

{{PMID Auto
|PMID=22336957
|Title=Impact of population diversity on the prediction of 7-SNP NAT2 phenotypes using the tagSNP rs1495741 or paired SNPs.
}}

{{PMID Auto
|PMID=22414877
|Title=Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1041983
|overall_frequency_n=3845
|overall_frequency_d=10758
|overall_frequency=0.357408
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=47
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23660777
|Title=Association of NAT1 and NAT2 genes with nonsyndromic cleft lip and palate.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}